Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%
Market cap
$15.0B
P/E
10.4×
Fwd P/E
39.0×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

8.35 8.87 7.95 9.39
P/S ratio
1.51 1.66 1.38 1.60
P/FCF ratio
254.48 0.00 0.00 0.00
P/Operating CF
167.42 145.22 (60.19) 58.70
P/B ratio
2.55 2.73 2.29 2.78
EV/Sales
1.94 2.17 1.95 2.19
EV/EBITDA
6.01 6.76 6.18 7.05
EV/FCF
326.38 (1,805.27) (79.32) (154.29)
Current Ratio
1.50 1.23 1.07 1.02
Net Debt/EBITDA
1.93 17.18 21.98 15.55
Debt/Equity
1.03 1.00 1.06 1.10
Earnings Yield
11.97% 11.27% 12.57% 10.65%
Free Cash Flow Yield
0.39% (0.07%) (1.78%) (0.89%)
Free Cash Flow per Share
(0.12) 0.18 (1.57) 0.83
Book value per Share
28.61 29.00 28.52 27.79
Free Cash Flow
(21.00) 32.00 (273.00) 144.00
EV/EBIT
7.44 8.28 7.63 8.77
Other line items

Show all line items

Columns are period end dates